Nanotechnology-based drug delivery systems for treatment of oral cancer: A review

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 3719-3735

  Calixto, Giovana ^a   Bernegossi, Jéssica ^a   Fonseca Santos, Bruno ^a   Chorilli, Marlus ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Oral cancer treatment; Oral squamous cell carcinoma; Targeted delivery

Indexed keywords

NANOPARTICLE;

DRUG DELIVERY SYSTEM; HUMAN; MOUTH NEOPLASMS; NANOMEDICINE;

DRUG DELIVERY SYSTEMS; HUMANS; MOUTH NEOPLASMS; NANOMEDICINE; NANOPARTICLES;

EID: 84905989521     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S61670     Document Type: Review

References (205)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
3. Epstein JB, Zhang L, Rosin M. Advances in the diagnosis of oral premalignant and malignant lesions. J Can Dent Assoc. 2002;68(10): 617-621.
4. Llewellyn CD, Johnson NW, Warnakulasuriya KA. Risk factors for oral cancer in newly diagnosed patients aged 45 years and younger: a case-control study in Southern England. J Oral Pathol Med. 2004; 33(9):525-532.
5. Chitapanarux I, Lorvidhaya V, Sittitrai P, et al. Oral cavity cancers at a young age: analysis of patient, tumor and treatment characteristics in Chiang Mai University Hospital. Oral Oncol. 2006;42(1):83-88.
6. Binnie WH, Rankin KV, Mackenzie IC. Etiology of oral squamous cell carcinoma. J Oral Pathol. 1983;12(1):11-29.
7. Douglass CW, Gammon MD. Reassessing the epidemiology of lip cancer. Oral Surg Oral Med Oral Pathol. 1984;57(6):631-642.
8. de Rosa I, Staibano S, Lo Muzio L, et al. Potentially malignant and malignant lesions of the lip. Role of silver staining nucleolar organizer regions, proliferating cell nuclear antigen, p53, and c-myc in differentiation and prognosis. J Oral Pathol Med. 1999;28(6):252-258.
9. Frierson HF Jr, Cooper PH. Prognostic factors in squamous cell carcinoma of the lower lip. Hum Pathol. 1986;17(4):346-354.
10. Näsman A, Attner P, Hammarstedt L, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer. 2009;125(2): 362-366.
11. Hafkamp HC, Speel EJ, Haesevoets A, et al. A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8. Int J Cancer. 2003;107(3):394-400.
12. Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer. 2007;121(8):1813-1820.
13. Huang B, Chen H, Fan M. A postulated role for human papillomavirus (HPV) in the transformation and proliferation of oral squamous cell carcinoma (OSCC). Med Hypotheses. 2008;70(5):1041-1043.
14. Petersen PE. Oral cancer prevention and control the approach of the World Health Organization. Oral Oncol. 2009;45(4-5):454-460.
15. Jones DL, Rankin KV. Oral cancer and associated risk factors. In: Cappelli DP, Mobley CC, editors. Prevention in Clinical Oral Health Care. St Louis, MO: Mosby Elsevier; 2008:68-77.
16. Su CC, Yang HF, Huang SJ, Lian IeB. Distinctive features of oral cancer in Changhua County: high incidence, buccal mucosa preponderance, and a close relation to betel quid chewing habit. J Formos Med Assoc. 2007;106(3):225-233.
17. Chen CJ, You SL, Lin LH, Hsu WL, Yang YW. Cancer epidemiology and control in Taiwan: a brief review. Jpn J Cancer Res. 2002;32 Suppl: S66-S81.
18. Kantola S, Parikka M, Jokinen K, et al. Prognostic factors in tongue cancer relative importance of demographic, clinical and histopathological factors. Br J Cancer. 2000;83(5):614-619.
19. Sankaranarayanan R, Masuyer E, Swaminathan R, Ferlay J, Whelan S. Head and neck cancer: a global perspective on epidemiology and prognosis. Anticancer Res. 1998;18(6B):4779-4786.
20. Carvalho AL, Magrin J, Kowalski LP. Sites of recurrence in oral and oropharyngeal cancers according to the treatment approach. Oral Dis. 2003;9(3):112-118.
21. Shah JP, Lydiatt W. Treatment of cancer of the head and neck. CA Cancer J Clin. 1995;45(6):352-368.
22. Onofre MA, Sposto MR, Navarro CM, Motta ME, Turatti E, Almeida RT. Potentially malignant epithelial oral lesions: discrepancies between clinical and histological diagnosis. Oral Dis. 1997;3(3):148-152.
23. Bhalang K, Suesuwan A, Dhanuthai K, Sannikorn P, Luangjarmekorn L, Swasdison S. The application of acetic acid in the detection of oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;106(3):371-376.
24. Epstein JB, Silverman S Jr, Epstein JD, Lonky SA, Bride MA. Analysis of oral lesion biopsies identified and evaluated by visual examination, chemiluminescence and toluidine blue. Oral Oncol. 2008;44(6): 538-544.
25. Wilder-Smith P, Lee K, Guo S, et al. In vivo diagnosis of oral dysplasia and malignancy using optical coherence tomography: preliminary studies in 50 patients. Lasers Surg Med. 2009;41(5):353-357.
26. Koch FP, Kaemmerer PW, Biesterfeld S, Kunkel M, Wagner W. Effectiveness of autofluorescence to identify suspicious oral lesions a prospective, blinded clinical trial. Clin Oral Investig. 2010;15(6): 975-982.
27. Koch FP, Kunkel M, Biesterfeld S, Wagner W. Diagnostic efficiency of differentiating small cancerous and precancerous lesions using mucosal brush smears of the oral cavity a prospective and blinded study. Clin Oral Investig. 2010;15(5):763-769.
28. Scully C, editor. Cancer. In: Oral and Maxillofacial Medicine: The Basis of Diagnosis and Treatment. 3rd ed. New York, NY: Churchill Livingstone Elsevier; 2013:204-217.
29. Csikar J, Aravani A, Godson J, Day M, Wilkinson J. Incidence of oral cancer among South Asians and those of other ethnic groups by sex in West Yorkshire and England, 2001-2006. Br J Oral Maxillofac Surg. 2013;51(1):25-29.
30. Weinberg MA, Estefan DJ. Assessing oral malignancies. Am Fam Physician. 2002;65(7):1379-1384.
31. Homer JJ, Greenman J, Stafford ND. Angiogenic cytokines in serum and plasma of patients with head and neck squamous cell carcimona. Clin Otolaryngol Allied Sci. 2000;25(6):570-576.
32. Weinberg RA. Tumor suppressor genes. Science. 1991;254(5035): 1138-1146.
33. Mehrotra R, Vasstrand EN, Ibrahim SO. Recent advances in understanding carcinogenicity of oral squamous cell carcinoma: from basic molecular biology to latest genomic and proteomic findings. Cancer Genomics Proteomics. 2004;1(4):283-294.
34. Khan Z, Bisen PS. Oncoapoptotic signaling and deregulated target genes in cancers: special reference to oral cancer. Biochim Biophys Acta. 2013;1836(1):123-145.
35. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet. 1993;9(4):138-141.
36. Mehrotra R, Yadav S. Oral squamous cell carcinoma: etiology, pathogenesis and prognostic value of genomic alterations. Indian J Cancer. 2006;43(2):60-66.
37. Hollstein M, Sidransky D, Vogelstein B, Harris CC. P53 mutations in human cancers. Science. 1991;253(5015):49-53.
38. Brennan JA, Boyle JO, Koch WM, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med. 1995;332(11):712-717.
39. Schantz SP. Basic science advances in head and neck oncology: the past decade. Semin Surg Oncol. 1995;11(3):272-279.
40. Califano J, Ahrendt SA, Meininger G, Westra WH, Koch WM, Sidransky D. Detection of telomerase activity in oral rinses from head and neck squamous cell carcinoma patients. Cancer Res. 1996;56(24): 5720-5722.
41. Miyoshi Y, Tsukinoki K, Imaizumi T, et al. Telomerase activity in oral cancer. Oral Oncol. 1999;35(3):283-289.
42. Brachman DG, Beckett M, Graves D, Haraf D, Vokes E, Weichselbaum RR. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res. 1993;53(16):3667-3669.
43. Harano N, Ono K, Hidaka K, Kai A, Nakanishi O, Inenaga K. Differences between orofacial inflammation and cancer pain. J Dent Res. 2010;89(6):615-620.
44. Peters CM, Lindsay TH, Pomonis JD, et al. Endothelin and the tumorigenic component of bone cancer pain. Neuroscience. 2004;126(4): 1043-1052.
45. Pickering V, Jordan RC, Schmidt BL. Elevated salivary endothelin levels in oral cancer patients a pilot study. Oral Oncol. 2007;43(1): 37-41.
46. Schmidt BL, Pickering V, Liu S, et al. Peripheral endothelin A receptor antagonism attenuates carcinoma-induced pain. Eur J Pain. 2007;11(4): 406-414.
47. Pickering V, Jay Gupta R, Quang P, Jordan RC, Schmidt BL. Effect of peripheral endothelin-1 concentration on carcinoma-induced pain in mice. Eur J Pain. 2008;12(3):293-300.
48. Nyberg P, Ylipalosaari M, Sorsa T, Salo T. Trypsins and their role in carcinoma growth. Exp Cel Res. 2006;312(8):1219-1228.
49. Lam DK, Schmidt BL. Serine proteases and protease-activated receptor 2-dependent allodynia: a novel cancer pain pathway. Pain. 2010;149(2):263-272.
50. Russo A, Soh UJ, Trejo J. Proteases display biased agonism at protease-activated receptors: location matters! Mol Interv. 2009;9(2): 87-96.
51. Amadesi S, Cottrell GS, Divino L, et al. Protease-activated receptor 2 sensitizes TRPV1 by protein kinase Cepsilonand A-dependent mechanisms in rats and mice. J Physiol. 2006;575(Pt 2):555-571.
52. Zheng J, Tian X, Sun Y, Lu D, Yang W. pH-sensitive poly (glutamic acid) grafted mesoporous silica nanoparticles for drug delivery. Int J Pharm. 2013;450(1):296-303.
53. Davis BM, Lewin GR, Mendell LM, Jones ME, Albers KM. Altered expression of nerve growth factor in the skin of transgenic mice leads to changes in response to mechanical stimuli. Neuroscience. 1993;56(4): 789-792.
54. Klein R, Jing SQ, Nanduri V, O'Rourke E, Barbacid M. The trk protooncogene encodes a receptor for nerve growth factor. Cell. 1991;65(1): 189-197.
55. Glinsky GV, Ivanova AB, Vinnitsky VB, Arumäe U, Siigur J, Neuman T. Nerve growth factor may be the metastasis growth factor. Ann N Y Acad Sci. 1987;496:656-659.
56. Kolokythas A, Cox DP, Dekker N, Schmidt BL. Nerve growth factor and tyrosine kinase A receptor in oral squamous cell carcinoma: is there an association with perineural invasion? J Oral Maxillofac Surg. 2010;68(6):1290-1295.
57. Ye Y, Dang D, Zhang J, et al. Nerve growth factor links oral cancer progression, pain, and cachexia. Mol Cancer Ther. 2011;10(9): 1667-1676.
58. Okada Y, Ueno H, Katagiri M, et al. Experimental study of antiangiogenic gene therapy targeting VEGF in oral cancer. Odontology. 2010;98(1):52-59.
59. Riedel F, Götte K, Schwalb J, Wirtz H, Bergler W, Hörmann K. Serum levels of vascular endothelial growth factor in patients with head and neck cancer. Eur Arch Otorhinolaryngol. 2000;257(6):332-336.
60. Shang ZJ, Li JR, Li ZB. Circulating levels of vascular endothelial growth factor in patients with oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2002;31(5):495-498.
61. Mǎrgǎritescu C, Pirici D, Simionescu C, et al. VEGF and VEGFRs expression in oral squamous cell carcinoma. Rom J Morphol Embryol. 2009;50(4):527-548.
62. Salimi M, Esfahani M, Habibzadeh N, et al. Change in nicotine-induced VEGF, PGE2 AND COX-2 expression following COX inhibition in human oral squamous cancer. J Environ Pathol Toxicol Oncol. 2012;31(4):349-356.
63. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7):1073-1081.
64. Del Prete A, Allavena P, Santoro G, Fumarulo R, Corsi MM, Mantovani A. Molecular pathways in cancer-related inflammation. Biochem Med (Zagreb). 2011;21(3):264-275.
65. Kamp DW, Shacter E, Weitzman SA. Chronic inflammation and cancer: the role of the mitochondria. Oncology (Williston Park). 2011;25(5):400-410.
66. Mignogna MD, Fedele S, Lo Russo L, Lo Muzio L, Bucci E. Immune activation and chronic inflammation as the cause of malignancy in oral lichen planus: is there any evidence? Oral Oncol. 2004;40(2): 120-130.
67. Li TJ, Cui J. COX-2, MMP-7 expression in oral lichen planus and oral squamous cell carcinoma. Asian Pac J Trop Biomed. 2013;6(8): 640-643.
68. Georgakopoulou EA, Achtari MD, Achtaris M, Foukas PG, Kotsinas A. Oral lichen planus as a preneoplastic inflammatory model. J Biomed Biotechnol. 2012;2012:759626.
69. Pontes HA, Pontes FS, Fonseca FP, et al. Nuclear factor kappa B and cyclooxygenase-2 immunoexpression in oral dysplasia and oral squamous cell carcinoma. Ann Diagn Pathol. 2013;17(1):45-50.
70. Mauro A, Lipari L, Leone A, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in normal and pathological human oral mucosa. Folia Histochem Cytobiol. 2010;48(4):555-563.
71. Goulart Filho JA, Nonaka CF, da Costa Miguel MC, de Almeida Freitas R, Galvão HC. Immunoexpression of cyclooxygenase-2 and p53 in oral squamous cell carcinoma. Am J Otolaryngol. 2009;30(2):89-94.
72. Impola U, Uitto VJ, Hietanen J, et al. Differential expression of matrilysin-1 (MMP-7), 92 kD gelatinase (MMP-9), and metalloelastase (MMP-12) in oral verrucous and squamous cell cancer. J Pathol. 2004;202(1):14-22.
73. Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev. 2000;14(17):2123-2133.
74. Werner JA, Rathcke IO, Mandic R. The role of matrix metalloproteinases in squamous cell carcinomas of the head and neck. Clin Exp Metastasis. 2002;19(4):275-282.
75. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Cancer. 2002;2(3):161-174.
76. Vairaktaris E, Serefoglou Z, Yapijakis C, et al. High gene expression of matrix metalloproteinase-7 is associated with early stages of oral cancer. Anticancer Res. 2007;27(4B):2493-2498.
77. Karin M. Nuclear factor-kappa B in cancer development and progression. Nature. 2006;441(7092):431-436.
78. Bindhu OS, Ramadas K, Sebastian P, Pillai MR. High expression levels of nuclear factor kappa B and gelatinases in the tumorigenesis of oral squamous cell carcinoma. Head Neck. 2006;28(10):916-925.
79. Richmond A. Nf-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol. 2002;2(9):664-674.
80. de Visscher JG. Behandeling en prognose van het mondholtecarcinoom [Treatment and prognosis of oral cancer]. Ned Tijdschr Tandheelkd. 2008;115(4):192-198. Dutch.
81. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21(1):92-98.
82. Bachaud JM, Cohen-Jonathan E, Alzieu C, David JM, Serrano E, DalySchveitzer N. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys.1996;36(5):999-1004.
83. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23(24):5568-5577.
84. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567-578.
85. Catimel G, Verweij J, Mattijssen V, et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol. 1994;5(6):533-537.
86. Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol. 1994;5(6):521-526.
87. Haddad R, Sonis S, Posner M, et al. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer. 2009;115(19): 4514-4523.
88. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11): 1116-1127.
89. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357(17):1695-1704.
90. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinumbased therapy. J Clin Oncol. 2007;25(16):2171-2177.
91. Terwogt JM, Schellens JH, Huinink WW, Beijnen JH. Clinical pharmacology of anticancer agents in relation to formulations and administration routes. Cancer Treat Rev. 1999;25(2):83-101.
92. Agüeros M, Ruiz-Gatón L, Vauthier C, et al. Combined hydroxypropylbeta-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel. Eur J Pharm Sci. 2009;38(4):405-413.
93. Devalapally H, Chakilam A, Amiji MM. Role of nanotechnology in pharmaceutical product development. J Pharm Sci. 2007;96(10): 2547-2565.
94. Kruijtzer CM, Beijnen JH, Schellens JH. Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. Oncologist. 2002;7(6):516-530.
95. Kumar GP, Rajeshwarrao P. Nonionic surfactant vesicular systems for effective drug delivery an overview. Acta Pharm Sin B. 2011;1(4): 208-219.
96. Manmode AS, Sakarkar DM, Mahajan NM. Nanoparticles-tremendous therapeutic potential: a review. International Journal of Pharm Tech Research. 2009;1(4):1020-1027.
97. Neha B, Ganesh B, Preeti K. Drug delivery to the brain using polymeric nanoparticles: a review. International Journal of Pharmaceutical and Life Sciences. 2013;2(3): 107-132.
98. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14(5): 1310-1316.
99. Couvreur P. Nanoparticles in drug delivery: past, present and future. Adv Drug Deliv Rev. 2013;65(1):21-23.
100. Kamimura M, Furukawa T, Akiyama S-I, Nagasaki Y. Enhanced intracellular drug delivery of pH-sensitive doxorubicin/poly(ethylene glycol)-block-poly(4-vinylbenzylphosphonate) nanoparticles in multidrug resistant human epidermoid KB carcinoma cells. Biomater Sci. 2013;1(4):361-367.
101. Du F, Meng H, Xu K, et al. CPT loaded nanoparticles based on betacyclodextrin-grafted poly(ethylene glycol)/poly(L-glutamic acid) diblock copolymer and their inclusion complexes with CPT. Colloids Surf B Biointerfaces. 2014;113:230-236.
102. Ravikumara NR, Tiyaboonchai W, Madhusudhan B. Fabrication and characterization of genistein encapsulated poly (D, L) lactic acid nanoparticles for pharmaceutical application. Curr Nanosci. 2013; 9(2):293-302.
103. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 2002;16(10): 1217-1226.
104. Ren F, Chen R, Wang Y, Sun Y, Jiang Y, Li G. Paclitaxel-loaded poly(n-butylcyanoacrylate) nanoparticle delivery system to overcome multidrug resistance in ovarian cancer. Pharm Res. 2011;28(4): 897-906.
105. Koo H, Min KH, Lee SC, et al. Enhanced drug-loading and therapeutic efficacy of hydrotropic oligomer-conjugated glycol chitosan nanoparticles for tumor-targeted paclitaxel delivery. J Control Release. 2013;172(3):823-831.
106. Lee KY, Mooney DJ. Alginate: properties and biomedical applications. Prog Polym Sci. 2012;37(1):106-126.
107. Das RK, Kasoju N, Bora U. Encapsulation of curcumin in alginatechitosan-pluronic composite nanoparticles for delivery to cancer cells. Nanomedicine. 2010;6(1):153-160.
108. Wang H, Zhao P, Liang X, et al. Folate-PEG coated cationic modified chitosan cholesterol liposomes for tumor-targeted drug delivery. Biomaterials. 2010;31(14):4129-4138.
109. Mohanraj VJ, Chen Y. Nanoparticles a review. Tropical Journal of Pharmaceutical Research. 2006;5(1):561-573.
110. Fan W, Yan W, Xu Z, Ni H. Formation mechanism of monodisperse, low molecular weight chitosan nanoparticles by ionic gelation technique. Colloids Surf B Biointerfaces. 2012;90:21-27.
111. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel). 2011;3(3):1377-1397.
112. Dhanda DS, Tyagi P, Mirvish SS, Kompella UB. Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose. J Control Release. 2013;168(3):239-250.
113. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9(8):615-627.
114. Chu KS, Schorzman AN, Finniss MC, et al. Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy. Biomaterials. 2013;34(33):8424-8429.
115. Mahapatro A, Singh DK. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J Nanobiotechnology. 2011;9(1):55.
116. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2012;64:206-212.
117. Brewer E, Coleman J, Lowman A. Emerging technologies of polymeric nanoparticles in cancer drug delivery. J Nanomater. 2011;(2011): 408675.
118. Damascelli B, Patelli GL, Lanocita R, et al. A novel intraarterial chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous cell carcinoma of the tongue: preliminary findings. AJR Am J Roentgenol. 2003;181(1):253-260.
119. Sulfikkarali N, Krishnakumar N, Manoharan S, Nirmal RM. Chemopreventive efficacy of naringenin-loaded nanoparticles in 7,12-dimethylbenz(a)anthracene induced experimental oral carcinogenesis. Pathol Oncol Res. 2013;19(2):287-296.
120. Yu D, Wang A, Huang H, Chen Y. PEG-PBLG nanoparticle-mediated HSV-TK/GCV gene therapy for oral squamous cell carcinoma. Nanomedicine (Lond). 2008;3(6):813-821.
121. Endo K, Ueno T, Kondo S, et al. Tumor-targeted chemotherapy with the nanopolymer-based drug NC-6004 for oral squamous cell carcinoma. Cancer Sci. 2013;104(3):369-374.
122. Li P, Zhou G, Zhu X, et al. Photodynamic therapy with hyperbranched poly(ether-ester) chlorin(e6) nanoparticles on human tongue carcinoma CAL-27 cells. Photodiagnosis Photodyn Ther. 2012;9(1): 76-82.
123. Dos Santos FK, Oyafuso MH, Kiill CP, Daflon-Gremiao MP, Chorilli M. Nanotechnology-based drug delivery systems for treatment of hyperproliferative skin diseases a review. Curr Nanosci. 2013;9(1):159-167.
124. Ribeiro de Souza AL, Kiill CP, dos Santos FK, et al. Nanotechnologybased drug delivery systems for dermatomycosis treatment. Curr Nanosci. 2012;8(4):512-519.
125. Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine. 2012;8(2): 147-166.
126. Souto EB, Doktorovová S. Chapter 6 solid lipid nanoparticle formulations pharmacokinetic and biopharmaceutical aspects in drug delivery. Methods Enzymol. 2009;464:105-129.
127. Wissing S, Kayser O, Müller R. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56(9):1257-1272.
128. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2):165-196.
129. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161-177.
130. Patel M, Souto EB, Singh KK. Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles. Expert Opin Drug Deliv. 2013;10(7):889-905.
131. Shi SJ, Zhong ZR, Liu J, Zhang ZR, Sun X, Gong T. Solid lipid nanoparticles loaded with anti-microRNA oligonucleotides (AMOs) for suppression of microRNA-21 functions in human lung cancer cells. Pharm Res. 2012;29(1):97-109.
132. Kakkar V, Singh S, Singla D, Kaur IP. Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin. Mol Nutr Food Res. 2011;55(3):495-503.
133. Holpuch AS, Hummel GJ, Tong M, et al. Nanoparticles for local drug delivery to the oral mucosa: proof of principle studies. Pharm Res. 2010;27(7):1224-1236.
134. Battaglia L, Gallarate M. Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery. Expert Opin Drug Deliv. 2012;9(5):497-508.
135. Fang JY, Fang CL, Liu CH, Su YH. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm. 2008;70(2): 633-640.
136. Lin YK, Huang ZR, Zhuo RZ, Fang JY. Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery. Int J Nanomedicine. 2010;5:117-128.
137. Kovacevic A, Savic S, Vuleta G, Müller R, Keck C. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure. Int J Pharm. 2011;406(1-2):163-172.
138. Aditya N, Shim M, Lee I, Lee Y, Im MH, Ko S. Curcumin and genistein coloaded nanostructured lipid carriers: In vitro digestion and antiprostate cancer activity. J Agric Food Chem. 2013;61(8): 1878-1883.
139. Zlotogorski A, Dayan A, Dayan D, Chaushu G, Salo T, Vered M. Nutraceuticals as new treatment approaches for oral cancer I: curcumin. Oral Oncol. 2013;49(3):187-191.
140. Chinsriwongkul A, Chareanputtakhun P, Ngawhirunpat T, et al. Nanostructured lipid carriers (NLC) for parenteral delivery of an anticancer drug. AAPS Pharm Sci Tech. 2012;13(1):150-158.
141. Wang J, Dai Y, Huang Y, et al. All-trans retinoic acid restores gap junctional intercellular communication between oral cancer cells with upregulation of Cx32 and Cx43 expressions in vitro. Med Oral Patol Oral Cir Bucal. 2013;18(4):e569-e577.
142. Liu SL, Zhong SS, Ye DX, Chen WT, Zhang ZY, Deng J. Repression of G protein-coupled receptor family C group 5 member A is associated with pathologic differentiation grade of oral squamous cell carcinoma. J Oral Pathol Med. 2013;42(10):761-768.
143. Liu D, Liu Z, Wang L, Zhang C, Zhang N. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B Biointerfaces. 2011;85(2):262-269.
144. Iida S, Shimada J, Sakagami H. Cytotoxicity induced by docetaxel in human oral squamous cell carcinoma cell lines. In Vivo. 2013;27(3): 321-332.
145. Zhang T, Chen J, Zhang Y, Shen Q, Pan W. Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide. J Pharm Sci. 2011;43(3):174-179.
146. Mishima K, Inoue K, Hayashi Y. Overexpression of extracellularsignal regulated kinases on oral squamous cell carcinoma. Oral Oncol. 2002;38(5):468-474.
147. Liu L, Tang Y, Gao C, et al. Characterization and biodistribution in vivo of quercetin-loaded cationic nanostructured lipid carriers. Colloids Surf B Biointerfaces. 2014;115:125-131.
148. Kang B, Mackey MA, El-Sayed MA. Nuclear targeting of gold nanoparticles in cancer cells induces DNA damage, causing cytokinesis arrest and apoptosis. J Am Chem Soc. 2010;132(5):1517-1519.
149. Wang F, Wang YC, Dou S, Xiong MH, Sun TM, Wang J. Doxorubicintethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells. ACS Nano. 2011;5(5):3679-3692.
150. El-Sayed IH, Huang X, El-Sayed MA. Surface plasmon resonance scattering and absorption of anti-EGFR antibody conjugated gold nanoparticles in cancer diagnostics: applications in oral cancer. Nano Lett. 2005;5(5):829-834.
151. Kah JC, Kho KW, Lee CG, et al. Early diagnosis of oral cancer based on the surface plasmon resonance of gold nanoparticles. Int J Nanomedicine. 2007;2(4):785-798.
152. Afifi MM, El Sheikh SM, Abdelsalam MM, et al. Therapeutic efficacy of plasmonic photothermal nanoparticles in hamster buccal pouch carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;115(6): 743-751.
153. Mezei M, Gulasekharam V. Liposomes a selective drug delivery system for the topical route of administration. Lotion dosage form. Life Sci. 1980;26(18):1473-1477.
154. Lian T, Ho RJ. Trends and developments in liposome drug delivery systems. J Pharm Sci. 2001;90(6):667-680.
155. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818-1822.
156. Pedroso de Lima MC, Simões S, Pires P, Faneca H, Düzgüneş N. Cationic lipid-DNA complexes in gene delivery: from biophysics to biological applications. Adv Drug Deliv Rev. 2001;47(2):277-294.
157. Konopka K, Fallah B, Monzon-Duller J, Overlid N, Düzgünes N. Serum-resistant gene transfer to oral cancer cells by Metafectene and GeneJammer: application to HSV-tk/ganciclovir-mediated cytotoxicity. Cell Mol Biol Lett. 2005;10(3):455-470.
158. Figueiró Longo JP, Muehlmann LA, Velloso NV, et al. Effects of photodynamic therapy mediated by liposomal aluminum-phthalocyanine chloride on chemically induced tongue tumors. Chemotherapy. 2012;1:103.
159. Velloso NV, Muehlmann LA, Longo JPF, et al. Aluminum-phthalocyanine chloride-based photodynamic therapy inhibits PI3K/Akt/Mtor pathway in oral squamous cell carcinoma cells in vitro. Chemotherapy. 2012;1:107.
160. Bahram M, Hoseinzadeh F, Farhadi K, Saadat M, Najafi-Moghaddam P, Afkhami A. Synthesis of gold nanoparticles using pH-sensitive hydrogel and its application for colorimetric determination of acetaminophen, ascorbic acid and folic acid. Colloids Surf A Physicochem Eng Asp. 2014;441:517-524.
161. Giri TK, Thakur A, Alexander A, Ajazuddin Badwaik H, Tripathi DK. Modified chitosan hydrogels as drug delivery and tissue engineering systems: present status and applications. Acta Pharm Sin B. 2012;2(5): 439-449.
162. Ruel-Gariépy E, Shive M, Bichara A, et al. A thermosensitive chitosanbased hydrogel for the local delivery of paclitaxel. Eur J Pharm Biopharm. 2004;57(1):53-63.
163. Obara K, Ishihara M, Ozeki Y, et al. Controlled release of paclitaxel from photocrosslinked chitosan hydrogels and its subsequent effect on subcutaneous tumor growth in mice. J Control Release. 2005;110(1): 79-89.
164. Konishi M, Tabata Y, Kariya M, et al. In vivo anti-tumor effect through the controlled release of cisplatin from biodegradable gelatin hydrogel. J Control Release. 2003;92(3):301-313.
165. Gurski LA, Jha AK, Zhang C, Jia X, Farach-Carson MC. Hyaluronic acid-based hydrogels as 3D matrices for in vitro evaluation of chemotherapeutic drugs using poorly adherent prostate cancer cells. Biomaterials. 2009;30(30):6076-6085.
166. Gao Y, Ren F, Ding B, et al. A thermo-sensitive PLGA-PEG-PLGA hydrogel for sustained release of docetaxel. J Drug Target. 2011;19(7): 516-527.
167. Hao T, Li Z, Qiao M, Fan Q, Zhang N, Chen D. [Preparation of docetaxel hydrogels for subcutaneous injection and their release profile in vitro]. Chinese Pharmaceutical Journal. 2009;24: 15. Chinese.
168. Shaker DS, Ghorab MK, Klingner A, Teiama MS. In-situ injectable thermosensitive gel based on poloxamer as a new carrier for tamoxifen citrate. Int J Pharm Pharm Sci. 2013;5(Suppl 4):429-437.
169. Konishi M, Tabata Y, Kariya M, et al. In vivo anti-tumor effect of dual release of cisplatin and adriamycin from biodegradable gelatin hydrogel. J Control Release. 2005;103(1):7-19.
170. Deurloo MM, Kop W, van Tellingen O, Bartelink H, Begg A. Intratumoural administration of cisplatin in slow-release devices: II. Pharmacokinetics and intratumoural distribution. Cancer Chemother Pharmacol. 1991;27(5):347-353.
171. Tauro JR, Gemeinhart RA. Extracellular protease activation of chemotherapeutics from hydrogel matrices: a new paradigm for local chemotherapy. Mol Pharm. 2005;2(5):435-438.
172. Casolaro M, Cini R, Del Bello B, Ferrali M, Maellaro E. Cisplatin/ hydrogel complex in cancer therapy. Biomacromolecules. 2009;10(4): 944-949.
173. Fang L, Wang H, Zhou L, Yu D. FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells. Toxicol Appl Pharmacol. 2011; 251(1):8-15.
174. Moura MJ, Gil MH, Figueiredo MM. Delivery of cisplatin from thermosensitive co-cross-linked chitosan hydrogels. Eur Polym J. 2013; 49(9):2504-2510.
175. Salamat-Miller N, Chittchang M, Johnston TP. The use of mucoadhesive polymers in buccal drug delivery. Adv Drug Deliv Rev. 2005; 57(11):1666-1691.
176. Emoto S, Yamaguchi H, Kamei T, et al. Intraperitoneal administration of cisplatin via an in situ cross-linkable hyaluronic acid-based hydrogel for peritoneal dissemination of gastric cancer. Surg Today. 2014;44(5):919-926.
177. Li J, Gong C, Feng X, et al. Biodegradable thermosensitive hydrogel for SAHA and DDP delivery: therapeutic effects on oral squamous cell carcinoma xenografts. PloS One. 2012;7(4):e33860.
178. Formariz TP, Urban MCC, da Silva Júnior AA, Gremião MPD, de Oliveira AG. Microemulsões e fases líquidas cristalinas como sistemas de liberação de fármacos [Microemulsion and liquid crystals as drug delivery systems]. Revista Brasileira de Ciências Farmacêuticas. 2005;41:301-313. Portuguese.
179. Chorilli M, Prestes PS, Rigon RB, Leonardi GR, Chiavacci LA, Scarpa MV. Desenvolvimento de sistemas líquido-cristalinos empregando silicone fluido de co-polímero glicol e poliéter funcional siloxano [Development of liquid-crystalline systems using silicon glycol copolymer and polyether functional siloxane]. Quim Nova. 2009;32:1036-1040. Portuguese.
180. Prestes PS, Chorilli M, Chiavacci LA, Scarpa MV, Leonardi GR. Physicochemical characterization and rheological behavior evaluation of the liquid crystalline mesophases developed with different silicones. J Dispers Sci Technol. 2009;31(1):117-123.
181. Manaia EB, Kaminski RCK, Soares CP, et al. Liquid crystalline formulations containing modified surface TiO2 nanoparticles obtained by sol-gel process. J Solgel Sci Technol. 2012;63(2):251-257.
182. de Castro Santana R, Fasolin LH, da Cunha RL. Effects of a cosurfactant on the shear-dependent structures of systems composed of biocompatible ingredients. Colloids Surf A Physicochem Eng Asp. 2012;398:54-63.
183. Ezrahi S, Aserin A, Garti N. Aggregation behavior in one-phase (Winsor IV) microemulsion systems. In: Kumar P, Mittal KL, editors. Handbook of Microemulsion Science and Technology. New York, NY: Marcel Dekker, Inc.; 1999:185-246.
184. Hosmer JM, Shin SH, Nornoo A, Zheng H, Lopes LB. Influence of internal structure and composition of liquid crystalline phases on topical delivery of paclitaxel. J Pharm Sci. 2011;100(4):1444-1455.
185. Myoung H, Hong SD, Kim YY, Hong SP, Kim MJ. Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma. Cancer Lett. 2001;163(2):191-200.
186. Kioi M, Shimamura T, Nakashima H, et al. IL-13 cytotoxin has potent antitumor activity and synergizes with paclitaxel in a mouse model of oral squamous cell carcinoma. Int J Cancer. 2009;124(6): 1440-1448.
187. Eckardt A, Sinikovic B, Hofele C, Bremer M, Reuter C. Preoperative paclitaxel/carboplatin radiochemotherapy for stage III/IV resectable oral and oropharyngeal cancer: seven-year follow-up of a phase II trial. Oncology. 2008;73(3-4):198-203.
188. Cheung MC, Pantanowitz L, Dezube BJ. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. Oncologist. 2005;10(6):412-426.
189. Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak A. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev. 2007;(4):CD004421.
190. Rizwan S, Assmus D, Boehnke A, et al. Preparation of phytantriol cubosomes by solvent precursor dilution for the delivery of protein vaccines. Eur J Pharm Biopharm. 2011;79(1):15-22.
191. Zeng N, Hu Q, Liu Z, et al. Preparation and characterization of paclitaxel-loaded DSPE-PEG-liquid crystalline nanoparticles (LCNPs) for improved bioavailability. Int J Pharm. 2012;424(1-2):58-66.
192. Martins MRFM, Veiga F. Promotores de permeação para a liberação transdérmica de fármacos: uma nova aplicação para as ciclodextrinas [Permeation enhancers in transdermal drug delivery systems: a new application of cyclodextrins]. Revista Brasileira de Ciências Farmacêuticas. 2002;38(1):33-54. Portuguese.
193. Li S, Purdy WC. Cyclodextrins and their applications in analytical chemistry. Chem Rev. 1992;92(6):1457-1470.
194. Zhang J, Ma PX. Cyclodextrin-based supramolecular systems for drug delivery: recent progress and future perspective. Adv Drug Deliv Rev. 2013;65(9):1215-1233.
195. Concheiro A, Alvarez-Lorenzo C. Chemically cross-linked and grafted cyclodextrin hydrogels: from nanostructures to drug-eluting medical devices. Adv Drug Deliv Rev. 2013;65(9):1188-1203.
196. Szejtli J, Osa T, editors. Comprehensive Supramolecular Chemistry. Vol 3: Cyclodextrins. Oxford: Elsevier Science Ltd; 1996. Szejtli J. Introduction and general overview of cyclodextrin chemistry. Chem Rev. 1996;98(5):1743-1754.
197. Veiga FJB. Complexos de Inclusão com Ciclodextrinas Hidrófilas: Caracterização Físico-Química e Biofarmacêutica [Inclusion complexes with hydrophilic cyclodextrins: Physico-chemical and biopharmaceutical characterization] [doctoral thesis]. Coimbra: University of Coimbra; 1996. Portuguese.
198. Sallas F, Darcy R. Amphiphilic cyclodextrins advances in synthesis and supramolecular chemistry. European J Org Chem. 2008;6: 957-969.
199. Hirayama F, Uekama K. Cyclodextrin-based controlled drug release system. Adv Drug Deliv Rev. 1999;36(1):125-141.
200. Ramineni SK, Cunningham LL, Dziubla TD, Puleo DA. Development of imiquimod-loaded mucoadhesive films for oral dysplasia. J Pharm Sci. 2013;102(2):593-603.
201. Jing J, Szarpak-Jankowska A, Guillot R, Pignot-Paintrand I, Picart C, Auzély-Velty R. Cyclodextrin/paclitaxel complex in biodegradable capsules for breast cancer treatment. Chem Mater. 2013;25(19): 3867-3873.
202. He H, Chen S, Zhou J, et al. Cyclodextrin-derived pH-responsive nanoparticles for delivery of paclitaxel. Biomaterials. 2013;34(21): 5344-5358.
203. Eifer AC, Thaxton CS. Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study. In: Hurst SJ, editor. Biomedical Nanotechnology: Methods and Protocols. New York: Humana Press; 2011:235-338.
204. Yang K, Wen Y, Wang C. [Clinical application of anticancer nanoparticles targeting metastasis foci of cervical lymph nodes in patients with oral carcinoma]. Hua Xi Kou Qiang Yi Xue Za Zhi. 2003;21(6): 447-450. Chinese.
205. Hull LC, Farrell D, Grodzinski P. Highlights of recent developments and trends in cancer nanotechnology research-View from NCI Alliance for Nanotechnology in Cancer. Biotechnol Adv. Epub 12 August, 2013.